History

Ongoing Clinical development: Supported by a global network of clinical partners who test SGM-101 in various indications, SurgiMab works to make fluorescence-guided surgery a routine standard of care.

Launch of the T1 Trial at LUMC: Testing the Feasibility of SGM-101 for Colorectal Cancer Detection and screening

Clinical data in lung cancer patients published

Continued Support: An additional €6.8M secured from historical investors to drive ongoing clinical development in Europe and the U.S.

Phase 3 Clinical Trial: Pivotal Phase III study begins in Europe and the U.S., with the first American patient enrolled in October 2019.

LARRC phase 3 clinical trial for patients with locally advanced or recurrent rectal cancer

Major Financing: €6.6M raised to prepare pivotal trials and support U.S. expansion.

SGM-101 Clinical Results in Colorectal Cancer published in the Lancet Gastroenterology & Hepatology.

SGM-101: Fast Track Designation.

European Expansion: Phase I/II trials launch at Leiden University Medical Center, Catharina Hospital, and Erasmus MC, confirming safety and potential in colorectal and pancreatic cancers.

First in Human Study: Phase I trial of SGM-101 begins at Montpellier Cancer Institute, evaluating safety and feasibility.

Additional Funding: €6.8M secured to advance toward clinical development.

SurgiMab Founded in Montpellier to bring fluorescence-guided surgery into clinical practice.

Initial Funding: €1.5M raised to kick off preclinical development of SGM-101.